Skip to main content
Signal8

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders

$JAGXPress releaseMay 28, 2026, 10:00 AM ETRead the release

Jaguar Health is advancing its FDA-approved drug crofelemer as a novel oral therapy for rare intestinal failure disorders, specifically microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF). The company highlighted proof-of-concept results showing a liquid formulation of crofelemer reduced the need for parenteral support (TPN/IV fluids) by up to 37% in MVID patients and up to 15% in SBS-IF patients.

Key figures

Drug Name
crofelemer
Phase Of Trial
pivotal
Nda target date
mid-2027
Tpn reduction mvid
up to 37%
Tpn reduction sbs if
up to 15%

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.